NASHUA, N.H.--(BUSINESS WIRE)--iCAD,
Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapies for the early
identification and treatment of cancer, today announced that Robert
Goodman, M.D., has been named to iCAD’s Board of Directors. Dr. Goodman
brings nearly 50 years of clinical experience, along with extensive
academic and leadership credentials. He is the first radiation
oncologist to serve on iCAD’s multidisciplinary Board.

“Dr. Goodman’s impressive clinical background, coupled with his business
leadership experience and prestigious academic affiliations, will make
him an invaluable addition to iCAD’s Board of Directors,” said Ken
Ferry, Chief Executive Officer of iCAD, Inc. “As a highly regarded
member of the radiation oncology community, we look forward to Dr.
Goodman’s guidance and insight as we continue to grow and strengthen the
Xoft business.”

Dr. Goodman is a renowned radiation oncologist who is credited with
pioneering the use of radiotherapy to treat women with breast cancer. He
has served as the Pancoast Professor and Chair of the Department of
Radiation Oncology at the University of Pennsylvania and Chair of
Radiation Oncology at St. Barnabas Medical Center. Additionally, he
served two years as Acting Executive Director of the Hospital of the
University of Pennsylvania. Dr. Goodman has also held faculty
appointments at several prestigious medical schools including Harvard
Medical School and University of Pennsylvania School of Medicine. He has
also led Radiation Therapy Resident Programs at the University of
Pennsylvania and Allegheny University Hospitals.

“Electronic Brachytherapy is quickly becoming a sought after treatment
option in the field of radiation oncology,” said Dr. Goodman. “The Xoft
System’s mobile capabilities and innovative delivery technology help
address some of the most challenging issues associated with
comprehensive cancer care in today’s clinical environment. I look
forward to joining iCAD’s esteemed board members in their commitment to
improving upon and expanding the availability of advanced treatment
options that play such a critical role in the lives of cancer patients.”

Dr. Goodman has been published extensively in highly respected
peer-reviewed journals and has been recognized by Castle-Connolly, Good
Housekeeping and Redbook as one of the top physicians in
America. He has also consistently been named as a “Top Doctor” by New
York Magazine, New Jersey Monthly and New Jersey Life,
among other publications.

Dr. Goodman is a Phi Beta Kappa graduate of Dartmouth College and
received his medical degree from the College of Physicians and Surgeons
of Columbia University. He trained in Internal Medicine and Radiation
Oncology at Harvard University and is triple-boarded in Internal
Medicine, Medical Oncology and Radiation Oncology.

About iCAD, Inc.

iCAD is an industry-leading provider of Computer-Aided Detection (CAD)
technologies, advanced image analysis, workflow solutions and radiation
therapies for the early identification and treatment of common cancers.
iCAD offers a comprehensive range of high-performance, upgradeable CAD
solutions for mammography and advanced image analysis and workflow
solutions for Magnetic Resonance Imaging, for breast and prostate
cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft
System, offers radiation treatment for early-stage breast cancer that
can be administered in the form of Intraoperative Radiation Therapy or
accelerated partial breast irradiation. The Xoft System is also cleared
for the treatment of non-melanoma skin cancer and gynecological cancers.
For more information, call (877) iCADnow, or visit www.icadmed.com.

Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve a number of known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited
to, the Company’s ability to defend itself in litigation matters, the
risks relating to the Company’s acquisition of Xoft including, the
expected benefits of the acquisition may not be achieved in a timely
manner, or at all; the Xoft business operations may not be successfully
integrated with iCAD’s and iCAD may be unable to achieve the expected
synergies, business and strategic objectives following the transaction,
the risks of uncertainty of patent protection; the impact of supply and
manufacturing constraints or difficulties; product market acceptance;
possible technological obsolescence; increased competition; customer
concentration; and other risks detailed in the Company’s filings with
the Securities and Exchange Commission. The words “believe”,
“demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”,
and similar expressions identify forward-looking statements. Readers are
cautioned not to place undue reliance on those forward-looking
statements, which speak only as of the date the statement was made. The
Company is under no obligation to provide any updates to any information
contained in this release. For additional disclosure regarding these and
other risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission, available on
the Investors section of our website at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov